Nanni Huser

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

Megan J. Bywater, Gretchen Poortinga, Elaine Sanij et al. · Cancer Cell · 2012 · 560 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner et al. · Cancer Research · 2010 · 513 citations

Medicine, Oncology, Pharmacology +16

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 186 citations

Life Sciences, Cancer Biology, Oncology +14

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

Karen Lundgren, Hong Zhang, John Brekken et al. · Molecular Cancer Therapeutics · 2009 · 170 citations · Full text

Medicine, Oncology, Pharmacology +12

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux et al. · ACS Medicinal Chemistry Letters · 2012 · 164 citations

Life Sciences, Oncology, Pharmacology +14